Competing Interests: S. Morbach: Within the last 3 years, Morbach has served on advisory boards of URGO GmbH (National Advisory Board DFU), Novo Nordisk Deutschland (Clinical Practitioners Advisory Board) and an international advisory board of Reapplix ApS and has received corresponding fees. He was also Vice President of the International Working Group on the Diabetic Foot Implementation and of D-FOOT International. He is a visiting researcher at the Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty, Heinrich-Heine-University Düsseldorf. R. Lobmann has received research funding (personally or at his personal disposal) either directly or in the form of monetary benefits (personnel, equipment, etc.): Fa. Urgo (Explorer Study, E2-SubStudy) As a speaker he received a fee or as a passive participant he received a reimbursement of costs (travel or accommodation costs, paid participation fees): Honorarium adviser: Amgen, Astra Zeneca, Biotec, Böhringer Ingelheim, GWT-TUD GmbH, Lilly, Medac MSD Sharp & Domme GmbH, Novo Nordisk, Roche, Sanofi Aventis, Sciaric, URGO, Wörwag Pharma. Reimbursement of costs: Lilly, Urgo, Wörwag. He has been a paid consultant/internal training consultant or similar for: Abbott, Biotec, Böhringer Ingelheim, Lilly, Mölnlycke, Novo Nordisk, URGO, Wörwag Pharma. Membership and position in scientific societies/professional associations and possibly other associations relevant to this training measure: Member of the board of the ADBW, spokesman of the regional societies of the DDG, member of the Diabetes Advisory Board of the State Government of Baden Württemberg, delegate for D-Foot International, member of the board of the German Diabetes Society (DDG; 2016–2020), spokesman of the DDG Working Group on the Diabetic Foot (2010–2020). A. Risse has been active within the last 3 years in advisory boards of URGO GmbH and Neubourg Skin Care and has received corresponding fees. For lecture and training activities he received fees from the company Serag Wiesner and from the Zentralverband Podologie. He is chairman of the commission for EADV of DDG. M. Eckhard has worked for the following companies within the last 5 years and has received corresponding fees: Berlin-Chemie (lectures), Boehringer-Ingelheim (lectures and consulting), Lilly Deutschland (lectures and consulting), Novo Nordisk (lectures and consulting), Sanofi (lectures). Accompanying offices: Chairman of the Hessian Diabetes Society e.V. (HDG, Regional Society of DDG), Member of the Board of Directors of the DDG Working Group on the Foot e. V., Member of the Committee of DDG Diabetologists in the DDG. Professional status: Medical Director of the university diabetes center at the University Hospital Gießen and Marburg GmbH (UKGM, Gießen site), Chief Physician of the GZW Diabetes Clinic Bad Nauheim. H. Reike discloses that the Mariannen-Hospital has received support for events organized by him from the companies Novo Nordisk Deutschland, Lilly Deutschland, Beurer, Emmerich. M. Spraul has worked for the following companies within the last 3 years and has received corresponding fees: Lilly Germany (lectures and consulting), Novo Nordisk (lectures and consulting), Abbott (consulting), Astra Zeneca (lectures), Neubourg Skin Care (lectures and consulting). M. Spraul discloses that the Mathias-Spital has received support from the companies Novo Nordisk Deutschland and Neubourg Skin Care for events organized by him. G. Rümenapf and E. Müller have no conflicts of interest.